PMID- 23706769
OWN - NLM
STAT- MEDLINE
DCOM- 20140904
LR  - 20211021
IS  - 1000-467X (Print)
IS  - 1944-446X (Electronic)
IS  - 1944-446X (Linking)
VI  - 32
IP  - 12
DP  - 2013 Dec
TI  - Safety of in vitro amplified HLA-haploidentical donor immune cell infusions for 
      childhood malignancies.
PG  - 661-6
LID - 10.5732/cjc.012.10298 [doi]
AB  - In vitro amplified human leukocyte antigen (HLA)-haploidentical donor immune cell 
      infusion (HDICI) is not commonly used in children. Therefore, our study sought to 
      evaluate its safety for treating childhood malignancies. Between September 2011 
      and September 2012, 12 patients with childhood malignancies underwent HDICI in 
      Sun Yat-sen University Cancer Center. The median patient age was 5.1 years 
      (range, 1.7-8.4 years). Of the 12 patients, 9 had high-risk neuroblastoma (NB) [7 
      showed complete response (CR), 1 showed partial response (PR), and 1 had 
      progressive disease (PD) after multi-modal therapies], and 3 had Epstein-Barr 
      virus (EBV)-positive lymphoproliferative disease (EBV-LPD). The 12 patients 
      underwent a total of 92 HDICIs at a mean dose of 1.6x10(8) immune cells/kg body 
      weight: 71 infusions with natural killer (NK) cells, 8 with cytokine-induced 
      killer (CIK) cells, and 13 with cascade primed immune cells (CAPRIs); 83 
      infusions with immune cells from the mothers, whereas 9 with cells from the 
      fathers. Twenty cases (21.7%) of fever, including 6 cases (6.5%) accompanied with 
      chills and 1 (1.1%) with febrile convulsion, occurred during infusions and were 
      alleviated after symptomatic treatments. Five cases (5.4%) of mild emotion 
      changes were reported. No other adverse events occurred during and after the 
      completion of HDIDIs. Neither acute nor chronic graft versus host disease (GVHD) 
      was observed following HDICIs. After a median of 5.0 months (range, 1.0-11.5 
      months) of follow-up, the 2 NB patients with PR and PD developed PD during 
      HDICIs. Of the other 7 NB patients in CR, 2 relapsed in the sixth month of 
      HDICIs, and 5 maintained CR with disease-free survival (DFS) ranging from 4.5 to 
      11.5 months (median, 7.2 months). One EBV-LPD patient achieved PR, whereas 2 had 
      stable disease (SD). Our results show that HDICI is a safe immunotherapy for 
      childhood malignancies, thus warranting further studies.
FAU - Zhang, Fei
AU  - Zhang F
AD  - State Key Laboratory of Oncology in South China; Department of Pediatric 
      Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, P. 
      R. China. sunxf@sysucc.org.cn, xiajch@sysucc.org.cn.
FAU - Sun, Xiao-Fei
AU  - Sun XF
FAU - Li, Yong-Qiang
AU  - Li YQ
FAU - Zhen, Zi-Jun
AU  - Zhen ZJ
FAU - Zheng, Hai-Xia
AU  - Zheng HX
FAU - Zhu, Jia
AU  - Zhu J
FAU - Wang, Qi-Jing
AU  - Wang QJ
FAU - Lu, Su-Ying
AU  - Lu SY
FAU - He, Jia
AU  - He J
FAU - Wang, Juan
AU  - Wang J
FAU - Pan, Ke
AU  - Pan K
FAU - Cai, Rui-Qing
AU  - Cai RQ
FAU - Chen, Yan
AU  - Chen Y
FAU - Weng, De-Sheng
AU  - Weng DS
FAU - Sun, Fei-Fei
AU  - Sun FF
FAU - Xia, Jian-Chuan
AU  - Xia JC
LA  - eng
PT  - Journal Article
DEP - 20130527
PL  - England
TA  - Chin J Cancer
JT  - Chinese journal of cancer
JID - 101498232
SB  - IM
MH  - Child
MH  - Child, Preschool
MH  - Cytokine-Induced Killer Cells/*immunology
MH  - Epstein-Barr Virus Infections/therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Graft vs Host Disease/etiology
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects
MH  - Humans
MH  - Immunotherapy, Adoptive
MH  - Infant
MH  - Killer Cells, Natural/*immunology
MH  - Lymphoproliferative Disorders/*therapy/virology
MH  - Male
MH  - Neuroblastoma/*therapy
MH  - Transplantation, Homologous
MH  - Treatment Outcome
PMC - PMC3870850
EDAT- 2013/05/28 06:00
MHDA- 2014/09/05 06:00
PMCR- 2013/12/01
CRDT- 2013/05/28 06:00
PHST- 2013/05/28 06:00 [entrez]
PHST- 2013/05/28 06:00 [pubmed]
PHST- 2014/09/05 06:00 [medline]
PHST- 2013/12/01 00:00 [pmc-release]
AID - cjc.012.10298 [pii]
AID - cjc-32-12-661 [pii]
AID - 10.5732/cjc.012.10298 [doi]
PST - ppublish
SO  - Chin J Cancer. 2013 Dec;32(12):661-6. doi: 10.5732/cjc.012.10298. Epub 2013 May 
      27.